TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival of NOX-A12 + anti-VEGF + Radiotherapy
|
Press Release2024, September 16 08:00 a.m. TME Pharma announces oral presentation at ESMO Congress 2024 with updated results from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma 2024, August 27 06:00 p.m. TME Pharma announces convocation of an extraordinary general meeting of shareholders 2024, August 12 07:00 p.m. TME Pharma provides update on resources allocated to the liquidity contract with Invest Securities |
EventsESMO Congress 2024
September 13 - 17 | Barcelona, Spain Health Tech Innovation Days (HTID Conference)
Aram Mangasarian 24th Annual Biotech in Europe Forum
Aram Mangasarian, Ewelina Staniuk BIO-Europe
Dirk Eulberg, Ewelina Staniuk TIDES Europe
Aram Mangasarian, Stefan Vonhoff Latest Analyst ReportInvest Securities |